Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0206 EUR | -3.29% | -0.96% | -22.85% |
07-02 | Starbreeze AB Provides Update on Operation Medic Bag | CI |
06-28 | Starbreeze AB Announces PAYDAY 3: "Chapter II: Boys in Blue" Out Now | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.85% | 45.21M | - | ||
+22.53% | 3,425B | C+ | ||
+17.88% | 93B | B | ||
+15.82% | 86.49B | B+ | ||
+50.55% | 57.57B | D+ | ||
-20.47% | 50.05B | B+ | ||
+38.23% | 48.65B | D+ | ||
-23.39% | 47.44B | B- | ||
+76.52% | 41.06B | D+ | ||
-4.63% | 26.86B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- STAR B Stock
- 2ST Stock
- Ratings Starbreeze AB